$460.33
1.30% today
Nasdaq, Sep 24, 06:45 pm CET
ISIN
US02043Q1076
Symbol
ALNY

Alnylam Pharmaceuticals, Inc Stock price

$454.41
+10.77 2.43% 1M
+163.71 56.32% 6M
+219.10 93.11% YTD
+182.58 67.17% 1Y
+253.63 126.32% 3Y
+319.91 237.85% 5Y
+361.11 387.04% 10Y
+442.86 3,834.29% 20Y
Nasdaq, Closing price Tue, Sep 23 2025
-4.51 0.98%
ISIN
US02043Q1076
Symbol
ALNY
Industry

Key metrics

Basic
Market capitalization
$59.6b
Enterprise Value
$57.7b
Net debt
positive
Cash
$2.9b
Shares outstanding
131.0m
Valuation (TTM | estimate)
P/E
negative | 521.2
P/S
24.2 | 16.7
EV/Sales
23.5 | 16.2
EV/FCF
negative
P/B
237.7
Financial Health
Equity Ratio
1.6%
Return on Equity
-414.6%
ROCE
-5.5%
ROIC
-11.0%
Debt/Equity
4.1
Financials (TTM | estimate)
Revenue
$2.5b | $3.6b
EBITDA
$-123.7m | $223.7m
EBIT
$-180.2m | $324.6m
Net Income
$-319.1m | $114.2m
Free Cash Flow
$-52.1m
Growth (TTM | estimate)
Revenue
5.0% | 58.8%
EBITDA
-178.3% | 286.1%
EBIT
-275.5% | 283.5%
Net Income
-337.8% | 141.1%
Free Cash Flow
-116.3%
Margin (TTM | estimate)
Gross
83.6%
EBITDA
-5.0% | 6.3%
EBIT
-7.3%
Net
-13.0% | 3.2%
Free Cash Flow
-2.1%
More
EPS
$-2.4
FCF per Share
$-0.4
Short interest
4.0%
Employees
2k
Rev per Employee
$1.0m
Show more

Is Alnylam Pharmaceuticals, Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,013 stocks worldwide.

Alnylam Pharmaceuticals, Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

39 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

31x Buy
79%
8x Hold
21%

Analyst Opinions

39 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast:

Buy
79%
Hold
21%

Financial data from Alnylam Pharmaceuticals, Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
2,462 2,462
5% 5%
100%
- Direct Costs 403 403
32% 32%
16%
2,059 2,059
1% 1%
84%
- Selling and Administrative Expenses 1,080 1,080
26% 26%
44%
- Research and Development Expense 1,160 1,160
7% 7%
47%
-124 -124
178% 178%
-5%
- Depreciation and Amortization 57 57
2% 2%
2%
EBIT (Operating Income) EBIT -180 -180
275% 275%
-7%
Net Profit -319 -319
338% 338%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about Alnylam Pharmaceuticals, Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Alnylam Pharmaceuticals, Inc Stock News

Neutral
Seeking Alpha
about 23 hours ago
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 23, 2025 8:00 AM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Conference Call Participants William Pickering - Sanford C. Bernstein & Co., LLC.
Neutral
PRNewsWire
6 days ago
Alnylam, a leader in RNA interference (RNAi) therapeutics, will utilize the AGD dataset to inform development of 'gene silencing' medicines Members leverage AI-powered dataset to accelerate pharma R&D, and ensure that disease-impacting discoveries benefit all people SAN DIEGO , Sept. 18, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), and Nashville Biosciences, LLC (NashBio), today announce...
Neutral
Seeking Alpha
14 days ago
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 12:20 PM EDT Company Participants Jeffrey Poulton - CFO & Executive VP Conference Call Participants Michael Ulz - Morgan Stanley, Research Division Presentation Michael Ulz Equity Analyst All right. Good afternoon, everyone, and thanks for joining us at the Morgan Stanley Glob...
More Alnylam Pharmaceuticals, Inc News

Company Profile

Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. It is the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases. The company was founded by John Kennedy Clarke, Paul R. Schimmel and Phillip A. Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Head office United States
CEO Yvonne Greenstreet
Employees 2,230
Founded 2002
Website www.alnylam.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today